ERBB2 and neoplasm: This triple combination—using OX40 agonism to step on the gas, CTLA-4 blockade to release the brakes, and vaccination using aDEC-205/HER2 to steer the immune response in the right direction—was able to generate profound CTL infiltration into the tumor leading to tumor regression (Fig. 1).